JP2006513220A5 - - Google Patents

Download PDF

Info

Publication number
JP2006513220A5
JP2006513220A5 JP2004563916A JP2004563916A JP2006513220A5 JP 2006513220 A5 JP2006513220 A5 JP 2006513220A5 JP 2004563916 A JP2004563916 A JP 2004563916A JP 2004563916 A JP2004563916 A JP 2004563916A JP 2006513220 A5 JP2006513220 A5 JP 2006513220A5
Authority
JP
Japan
Prior art keywords
disease
linear
pharmaceutical composition
compound
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004563916A
Other languages
English (en)
Japanese (ja)
Other versions
JP4675628B2 (ja
JP2006513220A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/040870 external-priority patent/WO2004058718A1/en
Publication of JP2006513220A publication Critical patent/JP2006513220A/ja
Publication of JP2006513220A5 publication Critical patent/JP2006513220A5/ja
Application granted granted Critical
Publication of JP4675628B2 publication Critical patent/JP4675628B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004563916A 2002-12-20 2003-12-22 4−オキソ−3−(1−オキソ−1h−イソキノリン−2−イルアセチルアミノ)−ペンタン酸のエステル誘導体およびアミド誘導体、ならびにカスパーゼインヒビターとしてのそれらの使用 Expired - Fee Related JP4675628B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43513302P 2002-12-20 2002-12-20
PCT/US2003/040870 WO2004058718A1 (en) 2002-12-20 2003-12-22 4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoic acid ester and amide derivatives and their use as caspase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006343613A Division JP2007070368A (ja) 2002-12-20 2006-12-20 4−オキソ−3−(1−オキソ−1h−イソキノリン−2−イルアセチルアミノ)−ペンタン酸のエステル誘導体およびアミド誘導体、ならびにカスパーゼインヒビターとしてのそれらの使用

Publications (3)

Publication Number Publication Date
JP2006513220A JP2006513220A (ja) 2006-04-20
JP2006513220A5 true JP2006513220A5 (cg-RX-API-DMAC7.html) 2007-02-15
JP4675628B2 JP4675628B2 (ja) 2011-04-27

Family

ID=32682166

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004563916A Expired - Fee Related JP4675628B2 (ja) 2002-12-20 2003-12-22 4−オキソ−3−(1−オキソ−1h−イソキノリン−2−イルアセチルアミノ)−ペンタン酸のエステル誘導体およびアミド誘導体、ならびにカスパーゼインヒビターとしてのそれらの使用
JP2006343613A Pending JP2007070368A (ja) 2002-12-20 2006-12-20 4−オキソ−3−(1−オキソ−1h−イソキノリン−2−イルアセチルアミノ)−ペンタン酸のエステル誘導体およびアミド誘導体、ならびにカスパーゼインヒビターとしてのそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006343613A Pending JP2007070368A (ja) 2002-12-20 2006-12-20 4−オキソ−3−(1−オキソ−1h−イソキノリン−2−イルアセチルアミノ)−ペンタン酸のエステル誘導体およびアミド誘導体、ならびにカスパーゼインヒビターとしてのそれらの使用

Country Status (8)

Country Link
US (2) US7612091B2 (cg-RX-API-DMAC7.html)
EP (1) EP1581501A1 (cg-RX-API-DMAC7.html)
JP (2) JP4675628B2 (cg-RX-API-DMAC7.html)
CN (1) CN100366612C (cg-RX-API-DMAC7.html)
AU (1) AU2003303345A1 (cg-RX-API-DMAC7.html)
CA (1) CA2511235A1 (cg-RX-API-DMAC7.html)
TW (1) TW200500343A (cg-RX-API-DMAC7.html)
WO (1) WO2004058718A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
PE20040728A1 (es) 2002-06-28 2004-10-23 Vertex Pharma Inhibidores de caspasa
US7612091B2 (en) 2002-12-20 2009-11-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
PE20050159A1 (es) * 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
AU2005223767B2 (en) * 2004-03-12 2011-12-01 Vertex Pharmaceuticals Incorporated Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
PL217743B1 (pl) * 2004-05-15 2014-08-29 Vertex Pharma Zastosowanie inhibitorów ICE/kaspazy-1 do leczenia napadów i konwulsji w epilepsji oraz zawierające je kompozycja farmaceutyczna i zestaw
CN1980658A (zh) 2004-05-27 2007-06-13 沃泰克斯药物股份有限公司 治疗自身炎性疾病的ice抑制剂
ES2312012T3 (es) * 2004-09-17 2009-02-16 Biomas Ltd. Nuevos compuestos de telurio y su uso como inmunomodulares.
WO2006057961A1 (en) * 2004-11-24 2006-06-01 Vertex Pharmaceuticals Incorporated 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
FR2923160B1 (fr) 2007-11-02 2013-07-26 Pasteur Institut Composes destines a prevenir ou traiter une infection virale.
JP6006908B2 (ja) 2010-11-05 2016-10-12 ブランダイス ユニバーシティBrandeis University Ice阻害化合物およびその使用
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
MX2016014731A (es) 2014-05-12 2017-05-04 Conatus Pharmaceuticals Inc Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
KR20180101418A (ko) 2015-12-31 2018-09-12 코나터스 파마슈티칼스, 인크. 간 질환의 치료에서의 카스파제 억제제의 사용 방법
CN107286091B (zh) * 2016-04-11 2020-06-19 中国海洋大学 一种胺基Sclerotiorin衍生物在制备抗结核药物中的应用
MX2019003889A (es) 2016-10-05 2019-08-12 Novartis Ag Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.
US11447497B2 (en) 2018-06-29 2022-09-20 Histogen, Inc. (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
CN113767097B (zh) * 2019-04-30 2025-03-14 株式会社Lg化学 半胱天冬酶抑制剂的前药
WO2022123062A1 (en) 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
DD232699A1 (de) 1983-11-18 1986-02-05 Adw Ddr Verfahren zur herstellung von chinazolin-4-on-3-alkansaeuren und deren estern
FR2582514B1 (fr) 1985-05-30 1988-02-19 Rhone Poulenc Sante Medicaments a base d'amides, nouveaux amides et leur preparation
US5714484A (en) 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5565430A (en) 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
EP0761680A3 (en) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
US6063794A (en) 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
BR9712987A (pt) 1996-10-11 2000-04-18 Warner Lambert Co Inibidores de enzima de conversão de interleucina-1beta de sulfonamida
CA2268098A1 (en) 1996-10-11 1998-04-23 Warner-Lambert Company Aspartate ester inhibitors of interleukin-1.beta. converting enzyme
AU6908398A (en) 1996-10-28 1998-05-22 Versicor Inc Fused 2,4-pyrimidinedione combinatorial libraries and biologically active fused 2,4-pyramidinediones
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
SK288186B6 (sk) 1999-05-07 2014-05-06 Encysive Pharmaceuticals, Inc. Deriváty kyseliny propiónovej, ktoré inhibujú väzbu integrínov na ich receptory, farmaceutické kompozície s ich obsahom a ich použitie
RU2263109C2 (ru) 1999-05-07 2005-10-27 Тексэс Байотекнолоджи Копэрейшн ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СЕЛЕКТИВНОГО ИНГИБИРОВАНИЯ СВЯЗЫВАНИЯ α4β1 ИНТЕГРИНА У МЛЕКОПИТАЮЩЕГО
AR026748A1 (es) * 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
KR100322546B1 (ko) 2000-05-08 2002-03-18 윤종용 독립적인 전원 전압을 사용하는 메모리와 메모리 컨트롤러간의 인터페이스 시스템
DE60131160T2 (de) * 2000-06-07 2008-08-07 Vertex Pharmaceuticals Inc., Cambridge Caspase-inhibitoren und ihre verwendungen
JP2004509120A (ja) * 2000-09-13 2004-03-25 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼ阻害剤およびそれらの用途
CA2447999C (en) * 2001-05-23 2011-04-26 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
JP2005509028A (ja) 2001-10-09 2005-04-07 バーテックス ファーマシューティカルズ インコーポレイテッド アスパラギン酸およびグルタミン酸誘導体ならびにそのジアゾケトン中間体を合成するための方法
EP1485107A1 (en) 2002-02-11 2004-12-15 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
EP1499898A2 (en) 2002-04-19 2005-01-26 Vertex Pharmaceuticals Incorporated Regulation of tnf-alpha
PE20040728A1 (es) * 2002-06-28 2004-10-23 Vertex Pharma Inhibidores de caspasa
US7612091B2 (en) * 2002-12-20 2009-11-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
FI117148B (fi) 2004-07-09 2006-06-30 Kone Corp Menetelmä ja laitteisto aksiaalivuo-kestomagneettitahtikoneen kokoonpanoa varten
US7296449B2 (en) * 2004-09-21 2007-11-20 Ball Corporation Dry hydraulic can shaping
WO2006057961A1 (en) 2004-11-24 2006-06-01 Vertex Pharmaceuticals Incorporated 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
JP2007040368A (ja) * 2005-08-02 2007-02-15 Ntn Corp プーリの固定構造

Similar Documents

Publication Publication Date Title
JP2005533825A5 (cg-RX-API-DMAC7.html)
JP2003535865A5 (cg-RX-API-DMAC7.html)
RU2005102094A (ru) Ингибиторы каспазы и их применение
JP2003534325A5 (cg-RX-API-DMAC7.html)
TWI726030B (zh) 一種btk激酶抑制劑的結晶形式及其製備方法
CA2401832A1 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
RU2005140657A (ru) Ингибиторы каспаз и их применение
JP2004509120A5 (cg-RX-API-DMAC7.html)
UA81808C2 (en) Normal;heading 1;heading 2;DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES, PROCESS FOR PREPARATION AND THERAPEUTIC USES THEREOF
CA2422708A1 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
JP2011517443A5 (cg-RX-API-DMAC7.html)
WO2004113352A1 (en) Silylated heterocyclylurea derivatives as cytokine-inhibitors
JP2009502922A5 (cg-RX-API-DMAC7.html)
JP2007525503A5 (cg-RX-API-DMAC7.html)
KR20200011388A (ko) Jnk 저해 활성을 갖는 신규한 이미다졸 유도체 및 이를 포함하는 약학적 조성물
JP2019523273A (ja) ベリノスタットの多形形態、およびその調製のためのプロセス
WO2024088910A1 (en) Process for the preparation of a gadolinium contrast agent
CN101939289A (zh) 用于制备伏立诺他的新方法
RU2007123615A (ru) Производные 3-[2-(3-ациламино-2-оксо-2н-пиридин-1-ил)-ацетиламино]-4-оксо-пентановой кислоты и их применение в качестве ингибиторов каспазы
JP5460614B2 (ja) アゼチジン誘導体、それらの調製、およびそれらの治療における適用
JP2022526015A5 (cg-RX-API-DMAC7.html)
JPH03193799A (ja) 3―(l―ピログルタミル)―l―チアゾリジン―4―カルボン酸およびその誘導体の製造方法
WO2015097850A1 (ja) 2-アミノニコチン酸ベンジルエステル誘導体の製造方法
KR101012917B1 (ko) 피롤 헵탄산 화합물의 신규한 결정형
FR2874012A1 (fr) Derives de pyrrole, leur preparation et leur utlisation en therapeutique